Novartis AG (NYSE: NVS) is 1.64% higher on its value in year-to-date trading and has touched a low of $74.09 and a high of $94.26 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NVS stock was last observed hovering at around $92.07 in the last trading session, with the day’s gains setting it 0.14% off its average median price target of $94.47 for the next 12 months. It is also 19.14% off the consensus price target high of $114.03 offered by analysts, but current levels are -21.3% lower than the price target low of $76.02 for the same period.
Currently trading at $92.21, the stock is 1.03% and 3.24% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.41 million and changing 0.15% at the moment leaves the stock 8.07% off its SMA200. NVS registered 4.56% gain for a year compared to 6-month gain of 7.38%.
The stock witnessed a 2.04% loss in the last 1 month and extending the period to 3 months gives it a 22.05%, and is 1.26% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.85% over the week and 1.15% over the month.
Novartis AG (NVS) has around 108000 employees, a market worth around $222.06B and $52.26B in sales. Current P/E ratio is 9.50 and Fwd P/E is 14.23. Profit margin for the company is 41.70%. Distance from 52-week low is 24.46% and -2.17% from its 52-week high. The company has generated returns on investments over the last 12 months (9.70%).
The EPS is expected to grow by 202.30% this year.
Novartis AG (NVS) Top Institutional Holders
The shares outstanding are 2.17B, and float is at 2.15B with Short Float at 0.22%.
Novartis AG (NVS): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 1.85% up over the past 12 months and Sanofi (SNY) that is -6.14% lower over the same period. Bristol-Myers Squibb Company (BMY) is 13.44% up on the 1-year trading charts.